References
  1. Tocut M, Rozman Z, Biro A, et al. Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 550 patients from spain (REVAS Registry). Arthritis Care Res (Hoboken). 2020;72(7):1001-1010..
  2. Rathmann J, Jayne D, Segelmark M, et al. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2020 Nov 30; keaa699.
  3. Sakai R, Tanaka E, Nishina H, et al. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database. Int J Rheum Dis . 2019;22(11):1978-1984.
  4. Konigsberg MW, Wu CH, Strauch RJ. Topical treatment for cutaneous mucormycosis of the upper extremity. J Hand Surg Am. 2020;45(12):1189.e1-1189.e5.
  5. Zhan HX, Lv Y, Zhang Y, et al. Hepatic and renal artery rupture due to Aspergillus and Mucor mixed infection after combined liver and kidney transplantation: a case report. Transplant Proc . 2008;40(5):1771-1773.
  6. Paul SR, Gable PS. Mucormycosis as the elusive cause of an aortic thrombus and tissue-obliterating abscess. Case Rep Hematol. 2019:4842150.
  7. Godara SM, Kute VB, Goplani KR, et al. Mucormycosis in renal transplant recipients: predictors and outcome. Saudi J Kidney Dis Transpl. 2011;22(4):751-756.
  8. Waki D, Nishimura K, Tokumasu H, et al. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine (Baltimore). 2020;99(8):e19173.
  9. Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, et al. Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis: influence on the disease outcome. J Rheumatol. 2020;47(3):407-414.
  10. Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infection. 2017;45(4):443-448.
  11. Lee SC, Li A, Calo S, et al. Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucorcircinelloides. Mol Microbiol. 2015;97(5):844-865.
  12. Inagaki N, Sugimoto K, Hosone M,  et al. Disseminated Mucor infection and thrombotic microangiopathy in lymphoma-associated hemophagocytic syndrome. Int J Hematol. 2008;88(3):355-356.
  13. Santos Silva J, Torres C, Clemente S, et al. Isolated Pulmonary Mucormycosis in an immunocompetent patient. Rev Port Cir Cardiotorac Vasc. 2019;26(2):151-153.
  14. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827-1832.
  15. Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis_mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6):359-367.
  16. KaKallenberg CG, Heeringa P. Complement system activation in ANCA vasculitis: A translational success story? Mol Immunol. 2015;68(1):53-56.
  17. García L, Pena CE, Maldonado RÁ, et al. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study. Clin Rheumatol. 2019;38(10):2819-2824.
Fig. 1 Chest CT scan of the patient on May 4, 2017.